Michael Briggs, WSP President, notes that, "WSP is focused on improving oncology drug discovery research through the use of patient tumor-derived models. We have established methods to viably and faithfully capture a patient’s tumor so that multiple potential therapies, including existing drugs, clinical candidates and novel compounds or formulations can be tested and compared directly in patients’ tumors for efficacy. These methods are expected to improve clinical translation of novel drugs and hopefully improve outcomes. WSP believes testing NMI's proprietary nanomedicines in these models will provide the data to confidently move into the clinic."
Working together, WSP and NMI hope to advance their ovarian cancer nanomedicines programs to the clinic by identifying patients who will be most responsive to these novel treatments. NMI's nanomedicines are designed to potentially overcome multidrug resistance and treatment failure, which a majority of ovarian cancer patients potentially face during the course of their disease. With an estimated 21,860 new cases projected in 2012 including approximately 15,500 deaths in the USA, epithelial ovarian cancer is the most lethal of gynecologic cancers due to its propensity to spread into the upper abdomen and other organs. This partnership represents another development for the growing biotechnology research community the Massachusetts Biomedical Initiatives (MBI) is creating in downtown Worcester.
NMI CEO and President, Tim Coleman, said, “Cancer research to date has not moved the needle on curing some of the most lethal cancers like ovarian cancer, where the five year survival rate is very low. This partnership will allow NMI to test our nanomedicines in a “pre-clinical"
About Woodland Strategic Partners
WSP is a contract research organization focused on bringing the most relevant biology to oncology research. Through the innovative use of primary patient tumor models we are able to better assess therapeutic activity of oncology compounds with the goal of more faithful prediction of clinical efficacy. While this remains a work-in-progress for the field, WSP has data from studies on 14 patient tumors with Sorafenib that models clinical performance in hepatocellular carcinoma. Additionally, data from another compound currently in Phase 2 clinical trials is anticipated to further augment the hypothesis that testing using primary tumors can provide critical translational information on future trial design. WSP is also bringing forward novel models of recurrent cancers that are the most refractory to treatment and represent the most significant unmet medical need in oncology today. For more information, visit http://www.woodlandstrategicpartners.com.
# # #
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is dedicated to designing, investigating, developing, and commercializing life-saving nanomedicines for the treatment of ovarian cancer. Ultimately, we believe our products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester and Wellesley, Massachusetts. For more information, please visit http://www.nemucore.com.